STOCKHOLM, Oct. 22, 2020 /PRNewswire/ --
Encouraging clinical safety data for ATOR-1017
The Phase I study with ATOR-1017 has progressed exceptionally
well and in August we presented interim data that showed a good
safety profile at clinically relevant dose levels. The dose
evaluation will continue with yet higher doses and we expect to
present safety and potentially efficacy data from the entire study
in the spring of 2021. At the same time, we have shown strong Proof
of Mechanism data for mitazalimab, while the ATOR-1015 program
reported side effects at high dose levels.The nature of the
reactions have lead to a need to re-design the planned clinical
trial in malignant melanoma and to perform additional preclinical
investigations. We will now focus our clinical investments to
ATOR-1017 and mitazalimab. Both programs have first-in-class
potential, and will move into clinical Phase II during 2021",
commented CEO Per Norlén.
SIGNIFICANT EVENTS JULY - SEPTEMBER
Mitazalimab:
- Positive biomarker data demonstrating Proof of Mechanism in
clinical Phase I study performed by
Janssen.
- Clinical development program defined. The CTA for the upcoming
Phase II study in pancreatic cancer is scheduled to be submitted in
December 2020.
ATOR-1015:
- Revised plan due to further evaluation of doses and adverse
reactions, leading to delay of Phase
Ib.
- US composition of matter patent granted.
ATOR-1017:
- Encouraging emerging safety data at clinically relevant dose
levels in the ongoing Phase I study.
Preclinical:
- Neo-X-Prime: New unique drug concept for tumorspecific
treatment launched at 11th World Bispecific Summit.
Other:
- Gayle Mills appointed Chief
Business Officer.
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD
Clinical focus on ATOR-1017 and
mitazalimab:
- Preparations to bring ATOR-1017 and mitazalimab to Phase II
efficacy studies in
2021.
- ATOR-1015: A partner will be sought for further clinical
studies.
FINANCIAL SUMMARY
July-September
2020
- Net sales, SEK 0.0 million
(4.3).
- Operating result, SEK -30.6
million
(-58.5).
- Result for the period, SEK -30.8
million
(-56.6).
- Earnings per share before and after dilution, SEK -0.43
(-0.79).
- Cash flow for the period, SEK -32.7
million
(-47.3).
- Cash and cash equivalents, incl. interest-bearing securities,
SEK 137.0 million (302.2)
January-September
2020
- Net sales, SEK 4.4 million
(4.4).
- Operating result, SEK -110.2
million
(-155.2).
- Result for the period, SEK -108.8
million
(-150.3).
- Earnings per share before and after dilution, SEK-1.52
(-2.11).
- Cash flow for the period, SEK 42.6
million (-27.8).
During the first quarter, the holdings in corporate bonds and
interest funds were divested, which had a positive effect on cash
flow.
Read the complete report in the pdf below.
Alligator will host a conference call today at 2:00 p.m. CEST for investors, analysts and media,
where CEO Per Norlén will present
and comment on the Q3 interim report and the focus of the clinical
operations. The conference will be held in English. All necessary
information to listen-in and ask questions are available on the
following link: https://financialhearings.com/event/12459.
For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com,
+46-46-540-82-00
Marie Svensson,
CFO, marie.svensson@alligatorbioscience.com,
+46-46-540-82-03
Cecilia Hofvander, Director IR &
Communications, cecilia.hofvander@alligatorbioscience.com, +
46-46-540-82-06
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46-46-540-82-00
The information was submitted for publication, through the
agency of the contact persons set out above, at 8:00 a.m. CEST on October
22, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets;
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc.). In
addition, the company has developed a novel concept for more
patient-specific immuno-therapy: Neo-X-Prime. Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--publ--interim-report-january-september-2020,c3220428
The following files are available for download:
https://mb.cision.com/Main/12681/3220428/1322195.pdf
|
Alligator Bioscience
AB (publ): Interim report January-September 2020
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-publ-interim-report-january-september-2020-301157705.html
SOURCE Alligator Bioscience